


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-200) ELEXACAF TOR
PRONUNCIATION el ex" a kaf' tor
THERAPEUTIC CLAIM Treatment of cystic fibrosis

CHEMICAL NAMES

1. 3-Pyridinecarboxamide, *N*-[(1,3-dimethyl-1*H*-pyrazol-4-yl)sulfonyl]-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1*H*-pyrazol-1-yl]-2-[(4*S*)-2,2,4-trimethyl-1-pyrrolidinyl]-
2. *N*-(1,3-dimethyl-1*H*-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1*H*-pyrazol-1-yl]-2-[(4*S*)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide

STRUCTURAL FORMULA



MOLECULAR FORMULA C₂₆H₃₄F₃N₇O₄S
MOLECULAR WEIGHT 597.7
TRADEMARK None as yet
SPONSOR Vertex Pharmaceuticals
CODE DESIGNATIONS VX-445
CAS REGISTRY NUMBER 2216712-66-0
UNII RRN67GMB0V
WHO NUMBER 11180

gbk